Abstract Body

Background: Currently the most prevalent transmitted resistance-associated mutations in Western European countries are Thymidine Analogue Mutations (TAMs). We hypothesize that in contrast to previously published data these mutations do not affect the efficacy of currently recommended first line combination antiretroviral therapy (cART) regimens with a low barrier to resistance development (GBR) (two NRTI and one NNRTI). This study analyzes the effect of transmitted single TAMs on efficacy of these regimens. Methodology: Treatment-naive Men who have Sex with Men (MSM) diagnosed with HIV between 2002 and 2012 were selected from the ATHENA national observational HIV cohort in the Netherlands. Patients were classified into three groups: (1) a single resistance-associated mutation on a TAM position (‘TAM group’), (2) a single resistance mutation on a non-TAM position or ≥2 resistance mutations (‘RAM group’), and (3) no resistance or only non-wildtype mutations (‘WT/non-WT’). Virological failure (VF) was defined as the first of <1 log10 decrease in HIV RNA 4-8 weeks after start of cART, 200 copies/Ml after 16 weeks. Time to VF was analyzed using proportional hazards models. Patients were censored at the date of treatment interruption, the date of the last available RNA measurement, or 64 weeks after starting cART, whichever was earliest. Active regimen was defined as a Genetic Susceptibility Score (GSS) ≥3. Results: Of the 2314 diagnosed MSM, 104 (4%) were in the TAM group (97 full active regimen), 126 in the RAM group (75 fully active regimen). In total, 249 (11%) patients experienced VF. Compared to patients in the WT/non-WT group, time to VF was not different for the TAM group (relative hazard [RH] 1.04 (95% CI 0.58-1.86, p=0.9) or for RAM with a fully active regimen (RH 0.60, 0.25-1.47), but was shorter in RAM with a non-fully active cART regimen (GSS <3) (RH 2.19, 1.19-4.03). In 1537 (66%) patients starting on 1 NNRTI + 2 NRTI, RH for VF was 1.26 (95% CI 0.59-2.70, p=0.5) in the TAM group, 0.61 (0.15-2.47; p=0.5) in the RAM group with fully active cART, and 2.82 (1.32-6.08; p=0.008) in the RAM group with non-fully active cART compared to WT/non-WT. No differences were observed for patients starting high GBR regimens. Pretreatment viral load <100000 cps/mL was associated with lower hazard of VF compared to ≥100000 cps/mL (RH 0.52, 95% CI 0.40-0.69, p=<0.001). Conclusions: The presence of a transmitted single TAM does not affect the efficacy of currently used first-line cART regimens.